None listed
Conditions
Interventions
Drug : - Open-label pre and post clinical trial comparison
- Depending on the type of clinical symptoms, either MYP (a 30% ethanol extract of Astragalus + Codonopsis) or MYPlus (90% ethanol extract of
Sponsors
Daejeon Korean Medicine Hospital of Daejeon University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Men and women aged between 13 and 70 who have generally been healthy and have no specific diseases that cause fatigue. ? Individuals who have been diagnosed as recovered from COVID-19 or those who have passed 4 weeks since their second vaccination dose, and are currently experiencing severe fatigue or brain fog symptoms to the extent that it disrupts their daily life. ? Individuals with an mKCFQ11 score of 60 or above, or those with brain fog symptoms measured by VAS scoring 5 or higher. ? Individuals who, after receiving a detailed explanation about this clinical trial and fully understanding it, voluntarily decide to participate (in the case of minors, with the consent of their guardians) and provide written consent to comply with precautions.
Exclusion criteria
Exclusion criteria: ? Individuals who are on continuous medication for conditions/symptoms other than fatigue (excluding hypertension, hyperlipidemia, and diabetes). ? Those with uncontrolled hypertension (SBP of 170mmHg or higher) or prescribed insulin injections, severe anemia (Hg 9.0 g/dL or less), renal function abnormality (creatinine at 1.2 times the upper limit of the normal range), liver dysfunction or biliary tract issues (AST or ALT or Total bilirubin at 2 times the upper limit of the normal range), and thyroid dysfunction (TSH less than 0.27uIU/ml or exceeding 4.2 uIU/ml). ? Individuals diagnosed with or undergoing treatment for cancer, autoimmune diseases, or other known severe illnesses. ? Those taking medicines or health functional foods for the treatment of fatigue and brain fog. ? Individuals deemed by the investigator to have significant physical or mental defects that prevent them from understanding and following the overall treatment of this clinical trial. ? Those who have participated in another clinical trial within a month prior to the screening test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| modified Korean Chalder Fatigue scale (mKCFQ11) | — |
Secondary
| Measure | Time frame |
|---|---|
| Multidimensional Fatigue Inventory (MFI-20), and VAS for fatigue and brain fog, SF-12 | — |
Countries
Korea, Republic of
Contacts
Public ContactChang-Gue Son
Daejeon University
Outcome results
None listed